Dr John Marshall previews the GI cancer studies being presented at ASCO with his picks for the ones to watch, and predicts that a plenary presentation may be practice-changing.

With this review of the new literature, Dr David Johnson wants to put the risks associated with proton pump inhibitors into perspective and quiet the noise.

These management strategies can help enhance the care of women with adnexal masses.

Dr Kristien Boelaert offers a case-based review of new guidelines from the American Thyroid Association on treating hyperthyroidism and thyrotoxicosis.

Dr David Kerr challenges the oncology community to come up with rational, meaningful clinical trials to clarify the biology of metastatic peritoneal disease in colorectal cancer.

Dr Gerald Chodak discusses the clinical implications of new data on recurrence patterns in prostate cancer patients following radical prostatectomy.

Previously thought to be 'anticoagulated,' patients with cirrhosis really might be hypercoagulable. Dr David Johnson explains why this paradox is a 'must understand' for all who manage this condition.

Reviewing recent research, Dr Jeffrey Weber concludes that an amalgam of host- and tumor-related markers will be the best indication of which patients should receive checkpoint inhibitors.

Dr Wilner and Dr Loh discuss approaches to optimizing the value of medical missions through local partnership and the organization 53rd Week.

Dr Szczech provides a sobering view on what extreme actions uninsured immigrants are taking to push their symptom boundaries to near death every week in order to get emergent hemodialysis.